Notice:
If you happen to see a question you know the answer to, please do chime in and help your fellow community members. We encourage our fourm members to be more involved, jump in and help out your fellow researchers with their questions. GATK forum is a community forum and helping each other with using GATK tools and research is the cornerstone of our success as a genomics research community.We appreciate your help!

Test-drive the GATK tools and Best Practices pipelines on Terra


Check out this blog post to learn how you can get started with GATK and try out the pipelines in preconfigured workspaces (with a user-friendly interface!) without having to install anything.

Please help me to interpret this line. How come I have this disease?

chr1 53676448 . G A 1495.77 PASS AC=1;AF=0.500;AN=2;BaseQRankSum=1.48;ClippingRankSum=-5.270e-01;DP=79;ExcessHet=3.0103;FS=4.485;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.775;QD=19.18;ReadPosRankSum=0.403;SOR=0.581;set=variant2 GT:AD:DP:GQ:PL:CGIANN_VARNAME:CGIANN_1000GAF:CGIANN_ESP6500AF 0/1:29,49:78:99:1524,0,780:-,NM_000098.2(CPT2) c.1102G>A (p.V368I):-,0.5:-,0.456405
chr1 53676986 . C . . . END=53678942;NT GT ./.
chr1 53679264 . T . . . END=53680317;NT GT ./.
chr1 53680529 . a . . . END=53681541;NT GT ./.
chr1 53681771 . G . . . END=53682332;NT GT ./.
chr1 53682540 . G . . . END=53683699;NT GT ./.

I only saw one mutation with quite some information, and several other lines without information. How come I have a cpt-2 deficiency?

Tagged:

Answers

  • andrewchenandrewchen Member
    edited July 2017

    More data (with several new lines)

    chr1 53580646 . C . . NT END=53600015;NT GT ./.
    chr1 53600201 . T . . NT END=53607949;NT GT ./.
    chr1 53608129 . C . . NT END=53662647;NT GT ./.
    chr1 53662853 . T . . NT END=53666319;NT GT ./.
    chr1 53666517 . A . . NT END=53667997;NT GT ./.
    chr1 53668182 . T . . NT END=53675682;NT GT ./.
    chr1 53675849 . C . . NT END=53675853;NT GT ./.
    chr1 53676448 . G A 1495.77 PASS AC=1;AF=0.500;AN=2;BaseQRankSum=1.48;ClippingRankSum=-5.270e-01;DP=79;ExcessHet=3.0103;FS=4.485;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.775;QD=19.18;ReadPosRankSum=0.403;SOR=0.581;set=variant2 GT:AD:DP:GQ:PL:CGIANN_VARNAME:CGIANN_1000GAF:CGIANN_ESP6500AF 0/1:29,49:78:99:1524,0,780:-,NM_000098.2(CPT2) c.1102G>A (p.V368I):-,0.5:-,0.456405
    chr1 53676986 . C . . NT END=53678942;NT GT ./.
    chr1 53679264 . T . . NT END=53680317;NT GT ./.
    chr1 53680529 . a . . NT END=53681541;NT GT ./.
    chr1 53681771 . G . . NT END=53682332;NT GT ./.
    chr1 53682540 . G . . NT END=53683699;NT GT ./.

  • SheilaSheila admin Broad InstituteMember, Broadie, Moderator admin

    @andrewchen
    Hi,

    Sorry for the delay. Can you tell us how you produced the VCF? Did you follow Best Practices?

    Thanks,
    Sheila

Sign In or Register to comment.